Pfizer and its partner BioNTech have announced that their mRNA vaccine for COVID-19 is safe and appears to generate a protective immune response in children as young as 5.
that their mRNA vaccine for COVID-19 is safe and appears to generate a protective immune response in children as young as 5.
On the advice of its vaccine advisory committee, the FDA asked vaccine makers to include more children in these studies earlier this year. “We don’t know whether there were cases of COVID-19 among children that were enrolled in the study and how those compared in those who received placebo versus those that received vaccine,” he said.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Pfizer says COVID-19 vaccine safe, effective for kids ages 5 to 11Pfizer and BioNTech released data saying its vaccine is safe and effective for kids 5-11.
Lire la suite »
Pfizer says COVID-19 vaccine works in kids ages 5 to 11Pfizer said Monday its COVID-19 vaccine works for children ages 5 to 11 and that it will seek U.S. authorization for this age group soon -- a key step toward beginning vaccinations for youngsters. The vaccine made by Pfizer and its German partner BioNTech already is available for anyone 12 and older.
Lire la suite »
Pfizer COVID-19 vaccine works in younger children, drugmaker saysPfizer says its COVID-19 vaccine is safe and likely to work in younger children, and it's planning to ask for permission to use it in kids as young as 5
Lire la suite »
Pfizer Says COVID-19 Vaccine Works In Kids Ages 5 To 11The drugmaker said it will seek emergency use authorization for this age group in the U.S. by the end of the month.
Lire la suite »
Pfizer says its Covid vaccine is safe and effective for childrenPfizer-BioNTech says its Covid-19 vaccine is safe and effective for children ages 5 to 11, and that the companies will submit their data to the FDA for emergency use authorization.
Lire la suite »